The Asthma Landscape in the United States
Asthma does not affect all communities equally. According to national health data, adults make up roughly 22.3 million of the asthma population, while about 4.5 million children under 18 live with the condition. Women, Black and Hispanic populations, and residents of low-income urban neighborhoods bear a disproportionate share of emergency department visits and hospitalizations. In places like the Bronx, New York, researchers have documented asthma prevalence and mortality rates significantly higher than in other parts of the city, a pattern echoed in cities from Chicago to Birmingham.
These disparities are not simply about biology. Housing quality, proximity to highways, occupational exposures, and inconsistent access to specialty care all shape who gets sick and who stays well. Understanding this context matters because clinical trials increasingly aim to enroll participants who reflect the populations most affected by asthma. The PASSAGE study, a real-world Phase IV investigation of the biologic tezepelumab, made a deliberate effort to include Black and African American participants, adolescents, and people with a history of smoking—groups often underrepresented in earlier research.
The treatment landscape itself is shifting. In April 2026, the FDA approved Breztri Aerosphere, a triple-combination inhaler, for patients aged 12 and older with asthma, marking the first fixed-dose triple therapy available for this condition in the United States. That approval rested on data from Phase III trials that enrolled thousands of participants across the country. Every medication on the pharmacy shelf got there because someone, somewhere, volunteered for a study.
What Participating in a Trial Actually Involves
Clinical trials are not one-size-fits-all. They are organized into phases, each with a distinct purpose. Phase I studies, which are less common for asthma, focus on safety and dosing in small groups. Phase II trials explore whether a drug works for a particular condition and refine the dosing. Phase III trials compare the investigational treatment against either a placebo or the current standard of care in large, often multi-center populations. Phase IV studies take place after a drug is already on the market, gathering real-world evidence on long-term effectiveness and safety across broader patient groups.
For someone with asthma, the most commonly encountered trials fall into Phase II through IV. A person with poorly controlled moderate-to-severe asthma might qualify for a biologic trial testing a monoclonal antibody targeting a specific inflammatory pathway. Someone with mild persistent asthma might enroll in a study comparing two maintenance inhalers. The Trial of Roflumilast in Asthma Management, or TRIM, currently recruiting through the American Lung Association's Airways Clinical Research Centers, is studying whether a phosphodiesterase-4 inhibitor can help adults with poorly controlled asthma and elevated body mass index—a group that often has fewer treatment options.
The experience of participating varies by protocol, but most trials share a common rhythm. After an initial screening visit to confirm eligibility—which might involve breathing tests, blood work, and a review of your medical history—you enter a treatment period. Some trials are randomized and double-blinded, meaning neither you nor the study team knows whether you are receiving the investigational drug or a placebo. Others are open-label, where everyone gets the active treatment. You will likely be asked to track symptoms in a diary, attend periodic clinic visits, and report any changes in your health. The study team monitors you closely, often more closely than a typical primary care relationship allows.
A common question is about cost. In most asthma clinical trials conducted in the United States, the investigational medication and all study-related tests are provided at no charge to the participant. Some trials also offer compensation for time and travel, though amounts vary by study length, visit frequency, and the sponsoring organization. The key is that you should never be asked to pay to participate in legitimate research.
Comparing Trial Types at a Glance
| Trial Phase | What It Studies | Typical Duration | Who Might Qualify | Key Benefit | Key Consideration |
|---|
| Phase II | Effectiveness and dosing | Several months to a year | People with a specific asthma subtype | Early access to novel mechanisms | Smaller sample; less known about risks |
| Phase III | Comparison against placebo or standard care | 6 months to 2+ years | Broader asthma population | Contributes to FDA approval decisions | Possibility of placebo assignment |
| Phase IV | Real-world safety and long-term outcomes | 1 year or longer | Diverse patient groups, including those often excluded from earlier trials | Medication already approved; real-world data | May require more frequent monitoring visits |
| Observational | Patterns, biomarkers, quality of life | Variable | Can include people not eligible for drug trials | No experimental intervention | No direct treatment access |
Finding a Trial That Fits
The starting point for most people is ClinicalTrials.gov, a database maintained by the National Library of Medicine. It lists thousands of actively recruiting asthma studies across the United States. You can filter by location, age group, trial phase, and recruitment status. Typing in your city or ZIP code narrows results to sites you can reasonably reach. Major academic medical centers—think Duke, Northwestern, the University of Arizona, Mount Sinai, and the University of California campuses—tend to run multiple asthma trials simultaneously. Private research organizations like Epic Medical Research also conduct Phase II through IV trials and may advertise locally.
Beyond the federal database, the American Lung Association maintains a network of Airways Clinical Research Centers that conduct investigator-initiated studies. These centers are spread across the country: Arizona, Illinois, New York, North Carolina, and Vermont are among the locations running the TRIM trial. Contacting a center directly can connect you with a research coordinator who can explain what is currently enrolling.
Your own pulmonologist or allergist can be another valuable resource. Specialists in busy urban practices often know which trials are recruiting locally and can help you assess whether a particular study aligns with your medical history. Keep in mind that every trial has inclusion and exclusion criteria—things like age, lung function, exacerbation history, current medications, and comorbidities. Being screened and found ineligible for one study does not mean you will be ineligible for others.
What to Ask Before You Enroll
Walking into a screening visit prepared with questions can make the difference between a good experience and a regrettable one. Here are a few worth asking the research coordinator or principal investigator:
- What is the purpose of this study, and what phase is it in?
- How many visits will I need to attend, and how long does each one last?
- Is there a chance I will receive a placebo, and if so, for how long?
- What happens to my asthma care after the trial ends?
- Who covers the cost of any side effects or unexpected medical issues?
- Can I continue seeing my regular doctor while participating?
The informed consent document you receive before enrolling should answer many of these questions in writing. Read it carefully. It is not a formality—it is a legal and ethical safeguard that outlines exactly what the study involves, what is expected of you, and what rights you retain, including the right to withdraw at any time without penalty.
One participant who went through an asthma biologic trial described the experience this way: "The team treated me with so much care. I felt heard, respected, and informed every step of the way." Another said, "Being part of a clinical trial gave me hope." These are not guarantees, but they reflect what well-run trials strive to provide: a structured, supportive environment where patients are partners in discovery, not just subjects.
Taking the Next Step
If your current asthma regimen leaves you short of breath more often than you would like, or if you are curious about emerging therapies that target the underlying biology of airway inflammation rather than just quieting symptoms, exploring clinical trials is a reasonable next move. Start by searching ClinicalTrials.gov with your location and the term "asthma." Reach out to a research center near you. Bring a list of questions to your next specialist appointment.
The treatments that will define asthma care a decade from now are being tested today. Some of them will fail. Some will succeed. All of them depend on people willing to raise their hands and say, "I want to try something different."
研究の知恵